TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient/visitor hand hygiene rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCW hand hygiene rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fibrosis based on histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction in liver stiffness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction in mean aspartate aminotransferase to platelet ratio index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction in activity of otospongiotic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in intensity and frequency of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of epilepsy
Endpoint domain: Adverse events/effects
Primary endpoint: Improved 1-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Higher hematocrit, hemoglobin, and reticulocyte count values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ≥75% reduction from baseline in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: DLQI score ≤5
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ScPGA 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Survival free of cardiac failure or MI
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in apoB/apoA1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: discomfort/pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overactive bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 10-year risk for fatal MI
Endpoint domain: Mortality/survival
Primary endpoint: reduction of hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Kneeling pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stages of labor duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelial denudation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective expert-reviewed response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival of patients after nephrectomy
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative PaO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Primary patency at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from clinically driven target lesion revascularization at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate through 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Incident lung cancer cases
Endpoint domain: Mortality/survival
Primary endpoint: Minimum SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial pressures of oxygen and carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of participants with HIV‐1 RNA level of less than 50 copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in CD4+ T‐cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean daily energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % body fat (%BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of blistering
Endpoint domain: Adverse events/effects
Primary endpoint: exudate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postnatal pain while walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to become pain free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume pain-free intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade III‐IV leucopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate craving reduction ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of interoceptive airway sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noradrenalin concentration decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average 24h plasma leptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak 24h plasma leptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Amplitude of the 24h plasma leptin curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in RV/LV ratio from baseline to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Periorbital ecchymosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Levels of LSaO2, MSaO2 and SLT90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mPAP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interpersonal skills development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First request of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale at rest and movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cured markedly effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual cycle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Odds of having MetS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calcium deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter malpositions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Emergency room use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Acute admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of repeat EA DNA-PCR being positive at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of repeat EA DNA-PCR being positive at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Readmission for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Risk stratification improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating miR‐323‐3p levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive executive functioning improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prolactin response to fenfluramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Muscle strength of knee extensors, knee flexors, plantarflexors and dorsiflexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait performance during fast walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular fitness level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Whole body bone area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Delayed hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nadir in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RTSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of days using rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood velocity of the internal carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wall shear stress (WSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADL ability measured by the mRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal thickness at the endothelial side of the incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal volume within the 10.0 mm circle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: measles vaccine-induced immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: high antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lymphoproliferative responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cyclic displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cyclic strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total BPP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV death and HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Anti-avenin antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frontal dysfunction scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum brain-derived neurotrophic factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of allergic manifestations in infancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: risk of skin prick test reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: risk of childhood allergic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean intraoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Patient Health Questionnaire‐9 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reductions in clinical severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: beneficial behavioural changes
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: severity of symptoms of depression and anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate/severe late rectal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Pruritus relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lessening of pruritus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Knowledge Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: width of keratinized gingiva gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stable or improved visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of severe visual acuity loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rhegmatogenous retinal detachment (RD)
Endpoint domain: Adverse events/effects
Primary endpoint: Spiritual Well-Being (SWB)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage decrease in serum PINP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in spine bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hemorheology and CD62p indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall positive experience with (in)GSH
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health benefits attributable to (in)GSH use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin fold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery of AC as scheduled
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Long-term survival time
Endpoint domain: Mortality/survival
Primary endpoint: Lymphocyte counts and CD14(+) monocytes HLA‐DR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of IL-6 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase of IL-10 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of TLR4 protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adoption of formal sun protection policies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: RSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of the tracheal tube
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recognition of acute suicide tendencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Recognition of diagnostic criteria for major depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Satisfaction with training programs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of ovarian failure at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean duration of menstrual flow at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Arterial elasticity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quality of life benefits
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Glasgow Outcome Scale-Extended scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disability Rating Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood concentration of landiolol hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain (VAS 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of peritoneal closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: global rating of performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lymphedema
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in arm volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: substance abuse treatment retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in OAB and severe OAB micturitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of amnesia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to recover accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of progressive period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of muscular weakness or cold paresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting serum total triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average improvement in vulvar appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average FSFI increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma LPL mass concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma EL mass concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of carboplatin with decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3/4 neutropenia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: G2/3 carboplatin hypersensitivity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Decreasing health literacy skills associated with self-reported satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: N(2)O waste gas concentrations in the anaesthetist's breathing zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Mean interval before motor function of the legs returned
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum cephalad spread achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in consumption of analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in anxiety status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in health status (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the vismodegib concentration-time curve from zero to 24 h (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infection at the cannulation site
Endpoint domain: Adverse events/effects
Primary endpoint: Haematomas at the cannulation site
Endpoint domain: Adverse events/effects
Primary endpoint: Site pain during dialysis
Endpoint domain: Adverse events/effects
Primary endpoint: auricular nerve sensory recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: stimulated salivary flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: spontaneous pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for second surgical procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall satisfaction 6 months after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean adhesion scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scored chromosome-type abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: response inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RIFG activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: functional frontostriatal connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adjusted mean difference in HSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of controlled patients (mean home blood pressure <135 and 85 mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of sudden death, cerebrovascular, cardiac, renal and vascular events
Endpoint domain: Mortality/survival
Primary endpoint: yearly cardiovascular morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: yearly mortality
Endpoint domain: Mortality/survival